Immunotherapy impact factor 2020
Witryna13 kwi 2024 · The aim of this study is to evaluate the factors affecting the objective response rate (ORR) after neoadjuvant therapy of taxol plus platinum (TP) regimen combined with programmed cell death ... WitrynaMonoclonal Antibodies in Immunodiagnosis and Immunotherapy is a peer-reviewed venue for promoting and sharing research rooted in hybridoma technology. ... three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) metric. Cites per document ... 2024: 1.367: Cites ...
Immunotherapy impact factor 2020
Did you know?
WitrynaAims and scope. Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas … WitrynaIn vivo experiments showed that Anlotinib was more effective in the treatment of GSDMB-positive bladder cancer than GSDMB-negative bladder cancer. Anlotinib can increase the secretion of antitumor-related factors in GSDMB-positive bladder cancer such as TNF-a and CD107a. In addition, Anlotinib also induced an increase in GSDMB protein …
WitrynaImmunotherapy Impact Factor by Web of Science. Index. SCIE/SSCI Impact Factor. 4.196 by WOS ... 2024 Impact Factor . 3.05 3.114 3.231. 2024 Impact Factor . 2.551 2.7 2.683. 2024 Impact Factor . 2.615 2.678 2.588. ... Impact Factor. Impact factor (IF) is a scientometric factor based on the yearly average number of citations on articles … WitrynaRecent advances in immunotherapies against infectious diseases. Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Behind the scenes …
Witryna13 kwi 2024 · The journal publishes articles on all aspects of tumor immunology and cancer immunotherapy and, in doing so, aims to enrich communication and advance … WitrynaImmunotherapy: Open Access. Journal h-index : 6. Journal cite score : 2.00. Journal impact factor : 0.92. Average acceptance to publication time (5-7 days) Average article processing time (30-45 days) Less than 5 volumes 30 days. 8 - 9 volumes 40 days. 10 and more volumes 45 days.
Witryna1 kwi 2024 · Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic …
Witryna3 lut 2024 · Therapeutic Advances in Vaccines and Immunotherapy (TAV) is a peer-reviewed open access journal which focuses on advances in the fields of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as an ever-growing repertoire of other immunotherapeutic interventions. The journal is a … phlegm always in back of throatWitrynaImmunotherapy Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 1750-743X. Immunotherapy Impact Factor IF 2024 2024 2024 - BioxBio t strap toddler shoesWitrynaJournal Announcements. JITC's latest Impact Factor of 12.485 was announced in the 2024 Journal Citation Reports (JCR), placing the journal in the top 12% of the … t strap wedding shoes factoriesWitrynaImmunotherapy Latest Journal's Impact IF 2024-2024 is 4.04. More IF Trend, Prediction, Ranking & Key Factor Analysis. Journal Search Engine. ... · The … phlegm and chfWitrynaCancer Immunology, Immunotherapy is a monthly peer-reviewed medical journal published by Springer Science+Business Media. According to the Journal Citation … phlegm and catarrhWitrynaLiczba wierszy: 13 · Immunotherapy Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 1750-743X. Immunotherapy Impact Factor IF … phlegm and bad taste in mouthWitrynaMary Ann Liebert, Inc., in partnership with the Rosalind Franklin Society has launched a prestigious annual award to recognize outstanding published peer-reviewed research by women and underrepresented minorities in science in each of the publisher’s peer-reviewed journals. The RFS / MAL Award in Science for Monoclonal Antibodies in ... phlegm and chest pain